Emerald Coast Hospice Medicare Approved Location: 421 Oak Ave, Panama City, Florida 32401 Phone: (850) 769-0055 |
News Archive
Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).
Stress is prevalent in modern society and can affect human health through its effects on appetite. However, knowledge about the neural mechanisms related to the alteration of the subjective level of appetite caused by acute stress in humans remains limited.
A recent study demonstrates that antibodies generated in response to mRNA-based COVID-19 vaccination target more epitopes across the spike protein.
Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.
› Verified 6 days ago